ghk-cu clinical trial human randomized The Tripeptide in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health Frontiers | Exploring the beneficial

Canadian Considerations and Sourcing Canadian researchers and those exploring peptide therapy face specific considerations around sourcing, legality, and practical access

The MHRA position, summarised by Lynda Scammell (head of borderline products at the MHRA) and reported in The Guardian on 4 April 2026, is that products which are sold for human use or which carry medicinal claims fall inside the Human Medicines Regulations 2012, and that the MHRA is investigating UK clinics making such claims about unregulated peptide products

PMID: 41574827 Bioeng Transl Med Nanoalbumin-prodrug conjugates prepared via a thiolation-and-conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T-cell infiltration

Suspected adverse reactions to any substance should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk